glp-1 receptor agonist kidney outcomes semaglutide flow trial 2024 results CKJ REVIEW agonists in patients with chronic disease and either overweight or obesit 🚨 Journal Club: FLOW Trial

Medical weight loss injections have been associated with improvements in glycemic control, insulin sensitivity, blood pressure, and lipid profile, making them valuable tools for addressing comorbidities commonly associated with obesity, such as type 2 diabetes and cardiovascular disease

Progress becomes harder to sustain

Introduction Today, GLP-1 drugs are most commonly used for diabetes and weight loss, but there is potential for GLP-1 therapies to transform healthcare by offering new solutions for managing chronic conditions

Im on week 2 and have lost 4 pounds, and I notice Im not hungry or craving anything

The questions theyre asking now are: What happens when I stop